Global supply partner for drugs, biologics and consumer health products, Catalent, has announced that it has completed the acquisition of pharmaceutical softgels developer and manufacturer, Accucaps.
No financial details have been revealed, but the acquisition is expected to substantially complement Catalent’s global over-the-counter prescription pharmaceutical softgel capabilities and capacity. Catalent will benefit from the addition of Accucaps’ portfolio of products supplied to pharmaceutical companies in North America, as well as two facilities offering integrated softgel development, manufacturing and packaging.
Accucaps has over 500 employees at its two facilities in Windsor and Strathroy, Ontario, who will join Catalent’s global network of 11 softgel technologies facilities. The Accucaps facilities house sizeable blistering, bottling and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s